Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $247K fell 34.8% year over year, behind the +4324.8% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +205.6% a year.
Context
- Financing cash flow amounted to 58.9% of revenue in FY2025, up 58.1 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -34.8% toward the trailing-twelve-month pace of +4324.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 19.77M USD
- Year-over-year change
- +9639.4%
- 4-year CAGR
- -45.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.77M | +9639.4% |
| FY2024 | 2024-12-31 | 203K | +36.2% |
| FY2023 | 2023-12-31 | 149K | -78.5% |
| FY2022 | 2022-12-31 | 693K | -99.7% |
| FY2021 | 2021-12-31 | 216.75M | — |
Financing Cash Flow vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 financing cash flow of $18.76M is the 6th largest of the 9 companies compared; the peer median is $26.91M.
- Its year-over-year change of +4324.8% is the highest of 9, against a peer median of +107.3%.
- Financing cash flow amounts to 54.6% of revenue for RPID, versus a peer median of 30.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $49.08M | +8.7% | +182.8% | 955.9% | |
| LTM Mar 2026 | $35.6M | +177.6% | — | 33.3% | |
| LTM Mar 2026 | $35.04M | +172.3% | +87.5% | — | |
| LTM Mar 2026 | $33.16M | +538.4% | -28.4% | — | |
| LTM Mar 2026 | $20.67M | +538.0% | +155.1% | 28.6% | |
| LTM Mar 2026 | $18.76M | +4324.8% | +205.6% | 54.6% | |
| LTM Mar 2026 | $9.64M | +42.3% | +253.4% | 17.2% | |
| LTM Mar 2026 | $504K | -99.1% | +2110.8% | 884.2% | |
| LTM Mar 2026 | $358K | -96.4% | — | 0.6% | |
| Peer median (excluding RPID) | $26.91M | +107.3% | +168.9% | 30.9% | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.84M | 4.02M | 4.75M | 3.87M | 4.03M |
| Change in Working Capital | (8M) | (5.33M) | 555K | (4.77M) | 6.06M |
| Accounts Receivables | (17K) | (364K) | (163K) | (1.99M) | 4.39M |
| Inventory | (6.77M) | (5.84M) | 1.19M | (335K) | 1.47M |
| Accounts Payables | (524K) | 1.48M | (3.46M) | 562K | 1.6M |
| Other Working Capital | (691K) | (602K) | 2.98M | (3.01M) | (1.39M) |
| Other Non-Cash Items | 23.19M | 728K | (1.02M) | 271K | 2.71M |
| Operating Cash Flow | (54.96M) | (58.55M) | (45.08M) | (44.15M) | (31.06M) |
| Capital Expenditures | (3.22M) | (6.74M) | (1.85M) | (1.37M) | (850K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (25.09M) | (179.23M) | (62.49M) | (35.04M) | (27.08M) |
| Sales of Investments | 15M | 92.5M | 106.49M | 73.06M | 42.26M |
| Other Investing Activities | 20K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (13.29M) | (93.47M) | 42.15M | 36.66M | 14.33M |
| Debt Repayment | (26.17M) | (33K) | (37K) | (35K) | 19.09M |
| Common Stock Issued | 164.11M | 0 | 0 | 238K | 1.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (940K) | 726K | 186K | 0 | (419K) |
| Financing Cash Flow | 216.75M | 693K | 149K | 203K | 19.77M |
| Effect of Forex Changes | 0 | 0 | 0 | (81K) | 0 |
| Net Change in Cash | 148.49M | (151.32M) | (2.78M) | (7.37M) | 3.04M |
| Free Cash Flow | (58.18M) | (65.29M) | (46.93M) | (45.52M) | (31.91M) |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.